Promedior Announces Issuance of Two Additional U.S. Patents
—Company Continues to Strengthen Intellectual Property Around Pentraxin-2 Therapeutics—
LEXINGTON, Mass., February 8, 2013 —
Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, today announced that the United States Patent and Trademark Office (USPTO) has recently issued Promedior two U.S. patents.
One of the patents, entitled "SAP Variants and Their Use" (U.S. Patent Number 8,329,659), builds on Promedior's estate of intellectual property that covers the compositions and uses of Pentraxin-2, also known as serum amyloid P (SAP). The second patent, "Conjoint Therapy for Treating Fibrotic Diseases" (U.S. Patent Number 8,247,370), strengthens Promedior's intellectual property based around the use of Pentraxin-2 therapeutics in the treatment of diseases involving fibrosis.
To support its business and strategy, Promedior has built and continues to build a strong intellectual property portfolio relating to its targeted Pentraxin-2 therapeutics. Through a combination of exclusive in-licensing of core technology intellectual property and inventions by the company, Promedior has positioned itself to successfully advance important Pentraxin-2 therapeutics to market, while maintaining a market dominant intellectual property position in the field of Pentraxin-2 therapeutics that treat diseases involving fibrosis.
"The issuance of these two additional patents in 2012 further validates the innovative nature of our Pentraxin-2 platform technology and the proprietary nature of our therapeutic approach and products. Promedior's patent estate now consists of 11 issued patents and 60 pending patent applications worldwide and we expect additional patent issuances in 2013 which will further strengthen our broad base of intellectual property," said Mark L. Lupher, Jr., Ph.D., Chief Scientific Officer of Promedior.
Promedior is a clinical-stage biotechnology company pioneering the development of targeted therapeutics to treat diseases involving fibrosis. Fibrosis is a harmful process that occurs in many diseases, when normal healthy tissue is replaced with excessive scar tissue, compromising function and ultimately leading to organ failure. Promedior's proprietary platform is based upon Pentraxin-2, a naturally-occurring human protein that is specifically active at the site of tissue damage and works as an agonist, potentially preventing and reversing fibrosis.
By acting as a master regulator upstream in the fibrosis cascade, Pentraxin-2 therapeutics harness the innate healing power of the immune system and open up new potential to treat a wide range of systemic fibrotic diseases for which there are no approved therapies. Promedior has successfully advanced lead therapeutic candidates in human clinical trials, and is initially focused on rare fibrotic diseases, including idiopathic pulmonary fibrosis (IPF) and myelofibrosis, and fibrovascular retinal diseases, such as Age Related Macular Degeneration (AMD). Promedior is backed by leading global healthcare venture investors, has a significant intellectual property estate relating to the discoveries and applications of Pentraxin-2 therapeutics and is led by an experienced management team.
For additional information about Promedior, please visit
The Yates Network